# OnCo record espac-3 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/espac-3/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "espac-3", "NCT00058201" ;
  schema:name "ESPAC-3"@en ;
  schema:alternateName "ESPAC-3 (v2)"@en, "ESPAC3"@en ;
  schema:description "ESPAC-3 compared the two adjuvant chemotherapies then available after pancreatic cancer surgery and found they gave the same survival, about 23 months, but gemcitabine caused half as many serious side effects; a companion cohort in ampullary and bile duct cancers is still the main randomised evidence for adjuvant chemotherapy in those rarer tumours."@en ;
  schema:url <https://onco.cc/trials/espac-3/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00058201> ;
  onco:status "completed" ;
  onco:tag "soc-trials" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/resectable-pdac/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/ampullary/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/drugs/leucovorin/>, <https://onco.cc/drugs/gemcitabine/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-espac-3-fluorouracil-vs-gemcitabine-adjuvant-neoptolemos-jama-2010/> .